Ypsomed recently announced that it will roll out its mylife App (available on Google Play and the App Store; screenshots below) to 16 countries by the end of April 2018. As of February 13, it was available in the Netherlands, Sweden, Denmark, Austria, Germany, Norway, and the UK. The app can retrieve and display real-time insulin delivery data from the Bluetooth-enabled mylife YpsoPump (secondary display), in addition to embedding a bolus calculator. The app cannot control the pump (e.g., it cannot send a bolus command from the app to pump), meaning the actual bolus from the calculator must be manually entered on the pump. Still, this secondary display is a big win for users, and a nice mobile stepping stone to smartphone control (expected in 2019).
The launch will correspond with the software update for YpsoPump, which had just begun as of November. We’re not sure which markets already have the update, and therefore in which markets the app has been introduced, if any. Data from the app can also be shared with providers and caregivers via pdf or the mylife Cloud.
The press release notes Ypsomed’s plans to incorporate data from the new connected mylife Unio Neva BGM “in the coming months,” further reducing the hassle of bolus calculation (for now, the user has to manually input blood glucose data). The Unio Neva BGM is slated to launch in March-April as per the F1H18 update. The company’s vision for a connected ecosystem (pump, BGM, app, computer software) is beginning to take form (see image below).
Later this year, Ypsomed anticipates integration with CGM (discussions ongoing with Abbott and Dexcom as of November), and it expects to develop a mylife Control App, allowing for remote bolusing in 2019 (trials to begin in 2019). As mentioned in F1H18, the Control App will be pivotal in Ypsomed’s aspirations to develop a closed loop system, which the company plans to test with YpsoPump in a pivotal trial in 2019. This pipeline is exciting for patients in Europe – though Ypsomed has a relatively small user base, we appreciate these moves to make diabetes management simpler. We wonder how it is thinking about bundled service and new business models, offering a whole package of diabetes hardware and software to EU payers. On that note, the company told us “our vision is to ensure freedom of choice for the user to provide them a flexible, personalized and most rational therapy.”
Now that most new meters have Bluetooth (albeit with very low penetration), it’s excellent to see more pumps following with embedded Bluetooth – and hopefully more display/control apps. Roche’s Accu-Chek Spirit Combo was quite early to add Bluetooth (no display app to our knowledge), and it’s also now Tandem’s t:slim X2 (US); SOOIL’s DANA pump (OUS); Ypsomed’s YpsoPump (OUS); Cellnovo’s new Android handset (EU); and Insulet’s under-FDA-review Omnipod Dash. We know Medtronic has Bluetooth-enabled pumps in the pipeline, but it has never confirmed specific timing on a launch. Dana’s pump in Korea is the only cleared pump available, to our knowledge, that does allow for direct smartphone control (no bridging device needed) – that has made it popular among AndroidAPS users in Korea and Germany. We hope to see all pump makers follow Dana’s lead and enable secure smartphone control from an app.
-- by Maeve Serino, Brian Levine, Adam Brown, and Kelly Close